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Objective: To evaluate the effects of minimal-dose aprotinin in patients 
undergoing coronary artery bypass grafting, we conducted a prospective 
randomized study. Methods: A total of 167 patients were randomized to 
receive no aprotinin treatment (control, n = 57), minimal-dose aprotinin 
(1.0 x 106 KIU; n = 55), or low-dose aprotinin (2.7 -- 0.5 x 106 KIU; n = 
55). Blood loss and transfusion requirements, parameters of clotting and 
fibrinolysis, renal function, and early graft patency rates were assessed. 
Results: Postoperative blood loss and transfusion requirements were signif- 
icantly (p = 0.01) lower in both the minimal-dose and low-dose groups than 
in the control group. The increase in D-dimer level after cardiopulmonary 
bypass was significantly (p < 0.05) less marked in the low-dose group than 
in the control group. The a2-plasmin inhibitor and plasminogen activator 
inhibitor-1 levels were significantly (p < 0.05) greater in the minimal-dose 
and low-dose groups than in the control group after bypass, suggesting the 
prevention of fibrinolysis by both aprotinin doses. No statistically signifi- 
cant differences in postoperative renal function and early vein graft patency 
rates were noted (control group, 93.8%; minimal-dose group, 98.5%; 
low-dose group, 92.3%; p -- 0.25). Conclusions: Aprotinin was not associated 
with a significant increase in the prevalence of renal dysfunction or early 
vein graft occlusion. Minimal-dose aprotinin inhibited enhanced fibrino- 
lytic activity and reduced blood loss and transfusion requirements after 
bypass equivalently to low-dose aprotinin. The dose of 1 x 106 KIU added 
to the pump prime may be acceptably effective in reducing blood loss in 
patients undergoing primary coronary operations. (J Thorac Cardiovasc 
Surg 1997;114:261-9) 
A Protinin has been reported to decrease postop- erative blood loss and transfusion requirements 
in patients undergoing cardiac operations. 1-4 The 
mechanisms of action of aprotinin in reducing blood 
loss are still controversial, although the drug has been 
shown to preserve platelet membrane receptor glyco- 
protein Ib, 5 to inhibit the intrinsic lotting system, 6 and 
to prevent fibrinolysis. 3-5' 7, 8 Although aprotinin mark- 
edly improved hemostasis, concerns about the side 
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effects of high-dose aprotinin such as early vein graft 
thrombosis and renal dysfunction have been raised. TM 
The possibility exists, therefore, that any reduced ose 
with hemostatic efficacy comparable with that of high- 
dose aprotinin could reduce the prevalence of the 
adverse side effects. Recently, half of the standard high 
dose of aprotinin reported by Royston and associates 1 
was reported to be effective]' s However, an accept- 
able minimal-dose regimen that would provide the 
best risk/benefit balance has not yet been suggested. 
The purpose of this study was to evaluate the 
effects of minimal-dose (1 × 106 KIU) aprotinin on 
blood loss and transfusion requirements, clotting 
and fibrinolysis, renal function, and early graft pa- 
tency in patients undergoing coronary artery bypass 
grafting (CABG). 
Methods 
Patient population, aprotinin administration, and sur- 
gical techniques. A prospective randomized study was 
performed on 167 patients undergoing primary isolated 
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CABG by one surgeon (T.I.). Seventy-eight patients were 
receiving aspirin or a nonsteroidal ntiinflammatory drug 
before the operation. Administration of these platelet- 
active drugs was discontinued at least 10 days before the 
operation in all patients. The patients were randomized 
into three groups according to the dose of aprotinin (1.4 
mg of aprotinin, or 10,000 kallikrein inactivator units per 
milliliter; Bayer Yakuhin Ltd., Osaka, Japan) by means of 
a computer-generated randomization table. The control 
group received no aprotinin treatment (n = 57); the 
minimal-dose group received 1 × 106 KIU aprotinin only 
in the cardiopulmonary b pass (CPB) priming solution 
(n = 55); and the low-dose group received 3 x 104 KIU/kg 
aprotinin in the priming solution and continuous infusion 
of aprotinin at a rate of 0.75 × 104 KIU/kg every hour 
during CPB 7 (n = 55). The mean dose of aprotinin in the 
low-dose group was 2.7 _+ 0.1 × 106 KIU (range 1.4 × 106 
to 4.0 × 106 KIU). So that the investigators would remain 
blinded to the protocol, only the perfusionists were in- 
formed regarding the administration of the regimen; 
surgeons and others participating in patient care were not. 
Before CPB was initiated, heparin sodium was adminis- 
tered at an initial dose of 300 IU/kg. Additional heparin 
was administered if the celite-activated dotting time 
(Hemochron 401, International Technidyne Corporation, 
Edison, N.J.) became less than 400 seconds. CPB was 
constructed with single two-staged right atrial cannulation 
and ascending aortic cannulation. The systemic tempera- 
ture was allowed to drift to 33 ° _+ 1 ° C and perfusion flow 
during CPB was maintained at 2.5 to 2.6 L/min. Blood 
cardioplegic solution at 30 ° + 1 ° C was delivered through 
the aortic root and completed vein grafts in an intermit- 
tent antegrade fashion. All patients igned a consent form 
approved by the Human Experimental Committee of 
Kurume University Hospital. 
Postoperative blood loss and transfusion requirements. 
Before closure of the sternotomy, chest tubes were in- 
serted and the volume of blood loss drained from the 
tubes was measured 3, 6, 12, and 24 hours after CPB. The 
use of homologous blood products was carefully con- 
trolled according to the hemoglobin level, which was 
measured at regular intervals. Red blood cells or whole 
blood was administered only if the hemoglobin level fell 
below 8.0 gm/dl. 12 The volume (milliliters) and number of 
units of all blood products including packed red cells, 
whole blood, platelets, fresh frozen plasma, and cryopre- 
cipitate administered to each patient in the first 24 hours 
after CPB were recorded. 
Blood samples. Blood samples were taken before ad- 
ministration of heparin, 15 minutes after protamine ad- 
ministration, and 12 hours after cessation of CPB. Blood 
samples were drawn in precooled tubes containing 1.8 ml 
of 0.13 mol/L trisodium citrate (SRL, Tokyo, Japan). The 
samples were centrifuged within 30 minutes at 2000g at 
4 ° C. An aliquot of the plasma was snap frozen and stored 
at -80 ° C until analysis. 
Laboratory assessments. Chromogenic peptide sub- 
strates and test specifications from Kabivitrum AB, Stock- 
holm, Sweden, were used for the following functional 
assays, with reference ranges in parentheses: antithrombin 
III (S-2238, 80% to 130%) and c~2-plasmin inhibitor 
(S-2251, 80% to 130%). 13' 14 Antithrombin III and oL 2- 
plasmin inhibitor were measured with a Hitachi model 101 
spectrophotometer (Hitachi Medical Corp., Tokyo, Ja- 
pan). Plasma fibrinogen was measured with the Clauss 
method. 15 The international standard 89/644 NIBSC (Na- 
tional Institute for Biological Standards and Control) was 
used for calibration. Thrombin-antithrombin I l l  com- 
plexes were determined by an enzyme immunoassay, and 
plasminogen activator inhibitor-1 levels were determined 
by an enzyme-linked immunosorbent assay purchased 
from Behringwerke AG, Marburg, Germany.16. 17
D-dimer plasma concentrations were determined by the 
enzyme-linked immunosorbent assay purchased from 
Boehringer Mannheim GmbH, Mannheim, Germany. 18 
Renal function. Blood and urine specimens for the 
measurements of renal function were obtained before the 
operation and 12 and 36 hours after CPB. The urinary 
output after CPB was recorded. Creatinine, osmolar, and 
free water clearances were calculated by standard formu- 
las. Fractional sodium excretion (%NaExc) and fractional 
potassium excretion (%KExc) in percent were calculated 
as follows: 
%NaEx c = ([NaJNap])/[Cru/Crp]) x 100 
%KExc = ([Ku/Kp]/[Cr,/Crp]) x 100 
where Na u is the concentration of urinary sodium, Nap is 
the concentration of serum sodium, Cru is the concentra- 
tion of urinary creatinine, Crp is the concentration of 
serum creatinine, K~ is the concentration of urinary 
potassium, and Kp is the concentration of serum potas- 
sium. 
Graft patency assessment. Graft angiography was per- 
formed on 120 patients (control group, n = 38; minimal- 
dose group, n = 41; low-dose group, n = 41) 7 to 47 days 
after the operation (median 25 days). Forty-seven of 167 
patients enrolled in this study were excluded from the 
postoperative angiographic study because of the following 
reasons: patient refusal (n = 28: control group, n = 9; 
minimal-dose group, n = 11; low-dose group, n = 8), 
technical difficulty for either vein or arterial graft access 
(n = 12: control group, n = 5; minimal-dose group, n = 3; 
low-dose group, n = 4), patient illness (n = 4: control 
group, n = 3; low-dose group, n = 1), and patient death 
(n = 3: control group, n = 2; low-dose group, n = 1). 
Selective injection of contrast material in all vein, internal 
thoracic artery, or right gastroepiploic artery grafts was 
carried out. A graft and a distal anastomosis were defined 
as patent if contrast material was seen to flow through the 
graft into the distal native coronary artery. 
Statistical analysis. The sample size calculation was 
based on estimates of blood loss determined in patients 
undergoing primary CABG at Kurume university Hospi- 
tal. The calculations indicated that it would be possible to 
show a difference greater than or equal to 1.2 standard 
deviations with a power of 90% and a significance l vel of 
5% if 55 patients were evaluated at each treatment group. 
All results were expressed as mean _+ standard error of 
the mean for continuous variables. Categoric values were 
analyzed by means of the )(2 test. The Kruskal-Wallis test 
was used to evaluate the differences of blood loss and 
transfusion requirements among the groups. Where the 
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Table I. Clinical and operative data 
Control Minimal dose Low dose p Value 
No. of patients 57 55 55 
Age (y) 61.2 _+ 1.3 64.4 _+ 1.2 63.2 _+ 1.1 0.17 
Sex (M/F) 41/16 43/12 35/20 0.24 
Body surface area (m 2) 1.64 _+ 0.02 1.65 _+ 0.02 1.64 _+ 0.03 0.99 
LVEF (->40%/<40%) 51/6 53/2 50/5 0.36 
NYHA (II-III/IV) 42/15 47/8 43/12 0.31 
Autologous blood volume do- 159 _+ 55 172 +_ 44 172 _+ 50 0.94 
nated preoperatively (ml) 
Preoperative use of platelet- 29/28 25/30 24/31 0.73 
active drugs* (Y/N) 
Dose of heparin (x l04 IU) 2.28 +_ 0.06 2.39 _+ 0.07 2.35 _+ 0.08 0.65 
Mean ACT during CPB (sec.) 545 _+ 22 593 _+ 24 598 _+ 22 0.41 
Duration of XCL (min) 66 _+ 4 74 _+ 3 68 _+ 4 0.24 
Duration of CPB (rain) 127 _+ 5 131 _+ 4 129 _+ 5 0.87 
No. of distal anastomoses 2.9 + 0.1 3.1 + 0.1 2.9 + 0.1 0.31 
No. of arterial grafts 1.2 _+ 0.i 1.3 _+ 0.1 1.2 _+ 0.1 0.53 
There were no significant differences among the groups for any of the parameters li ted. LVEF, Left ventricular ejeciion fraction; NYHA, New York Heart 
Association functional class; ACT, activated clotting time; XCL, aortic crossclamp; CPB, cardiopulmonary bypass. 
*Aspirin or a nonsteroidal ntiinflammatory drug. 
Table II. Preoperative and postoperative hemoglobin concentrations (gm/dl) 
Control Minimal dose Low dose 
(n = 57) (n = 55) (n 55) p Value 
Preop. 13.4 _+ 0.2 12.6 _+ 0.2 13.4 _+ 0.3 0.20 
0 hr 8.3 -+ 0.1 8.5 _+ 0.2 8.2 _+ 0.1 0.39 
24 hr 10.9 + 0.2 10.9 _+ 0.2 11.4 _+ 0.2 0.10 
Preop., Preoperative; 0hr, immediately after cessation of CPB; 24 hr, 24 hours after cessation of CPB. Other abbreviations as listed in Table I. 
overall test indicated significant between-group differ- 
ences, pairwise comparisons among the three treatment 
groups were made. Because of the increased risk of type 
I error caused by multiple comparisons, a p value less 
than 0.01 was considered significant for these pairwise 
comparisons. A two-way repeated-measures analysis of 
variance was used to test the effect of study groups and 
sampling time points on parameters of clotting and 
fibrinolysis and on renal function. When the two-way 
repeated-measures analysis of variance indicated a sig- 
nificant effect of group or time (p < 0.05), the differ- 
ences were specified with one-way analysis of variance 
and Duncan's multiple range test. A p value less than 
0.05 was considered significant. 
Results 
Clinical and operative data of the three patient 
groups are shown in Table I. No significant differ- 
ences were noted in age, sex, body surface area, 
ejection fraction, New York Heart Association 
functional class, autologous blood volume donated 
before the operation, preoperative aspirin use, 
crossclamp time, CPB time, number of distal anas- 
tomoses, and number of arterial grafts. 
Hemoglobin concentration, blood loss, and trans- 
fusion requirements. No statistically significant 
differences were measured in the hemoglobin 
concentration among the groups at any time (Ta- 
ble II). Postoperative blood loss and transfusions 
of packed red cells and all blood products during 
the first 24 hours after CPB were significantly (p = 
0.001) lower in minimal-dose and low-dose groups 
than in the control group (Table III). The num- 
bers of patients who required transfusion of any 
donor blood products were 46 (80.7%) in the 
control group, 31 (56.4%) in the minimal-dose 
group, and 35 (63.6%) in the low-dose group (p = 
0.02). No statistically significant differences in 
postoperative blood loss and transfusion require- 
ments were seen between patients in the minimal- 
dose and low-dose groups. 
Clotting and fibrinolytic systems. The parame- 
ters of clotting and fibrinolysis are shown in Figs. 1 
and 2. The antithrombin III and fibrinogen levels 
were significantly (p < 0.05) decreased after CPB in 
all groups; however, no significant differences in 
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Table III. Postoperative blood loss and transfusion requirements 
Control Minimal dose Low dose 
(n = 57) (n = 55) (n = 55) p Value 
Blood loss (ml) 
3 hr 104 _+ 11 72 _+ 8 73 _+ 6 0.082 
6 hr 236 _+ 31 172 _+ 15 166 _+ 11 0.329 
12 hr 364 _+ 37 280 _+ 22 247 +_ 13 0.051 
24 hr 535 _+ 39 415 _+ 27* 368 + 17" 0.001 
Transfusion requirements 
Packed red cells 570 _+ 40 ml 379 _+ 38 ml* 375 _+ 40 ml* 0.001 
4.3 _+ 0.3 U 2.9 _+ 0.3 U* 2.8 + 0.3 U* 
(Patients) (46) (31) (35) (0.02) 
Whole blood 11 + 8 ml 0 ml 0 ml 0.18 
0.1 + 0.1U 0U 0U 
(Patients) (2) (0) (0) (0.i4) 
Platelets 0 ml 0 ml 0 ml - 
0U  0U 0U 
(Patients) (0) (0) (0) - 
Fresh frozen plasma 69 _+ 17 ml 51 _+ 15 ml 48 -- 15 ml 0.61 
0.9 +- 0.2 U 0.6 -+ 0.2 U 0.6 _+ 0.2 U 
(Patients) (13) (11) (9) (0.69) 
Cryoprecipitate 44 _+ 18 mI 27 _+ 12 ml 27 _+ 14 ml 0.66 
0.2 _+ 0.1 U 0.1 + 0.1 U 0.1 + 0.1 U 
(Patients) (5) (4) (5) (0.93) 
All blood products 694 _+ 38 ml 457 _+ 36 ml* 450 _+ 38 ml* 0.001 
5.7 _+ 0.8 U 3.6 _+ 0.8 U* 3.5 _+ 0.8 U* 
(Patients) (46) (31) (35) (0.02) 
Blood loss and transfusion of packed red cells and all blood products 24 hours after cessation of CPB were significantly ower in the minimal-dose and 
low-dose groups than in the control group. The p values refer to the results of the Kruskal-Wallis test for transfusion requirements and X 2 test for number 
of patients. Abbreviations as listed in Table I. 
*p < 0.01 versus control. 
those parameters were found among the groups at 
any time point. The thrombin-antithrombin III com- 
plexes significantly (p < 0.05) increased after CPB 
and remained significantly high until 12 hours after 
CPB in all groups; however, no significant differ- 
ences were found among the groups at any time 
point. The plasminogen activator inhibitor-1 de- 
creased significantly after CPB in the control group, 
and the level was significantly (p < 0.05) lower than 
that in the minimal-dose and low-dose groups after 
CPB. The level of o~2-plasmin hibitor was signifi- 
cantly (p < 0.05) decreased after CPB in the control 
group, whereas it increased significantly (p < 0.05) 
after CPB in the minimal-dose and low-dose groups. 
The o~2-plasmin i hibitor level after CPB was signif- 
icantly greater in the minimal- and low-dose groups 
than in the control group (p < 0.05). A marked 
increase (p < 0.05) in D-dimer levels was found in 
the control group after CPB, and the increase 
persisted until 12 hours after CPB. In contrast, 
D-dimer levels remained essentially constant in the 
low-dose group. The D-dimer level was significantly 
greater in the control group than in the low-dose 
group immediately after CPB and 12 hours after 
CPB. 
Renal function parameters. Repeated-measures 
analysis of variance demonstrated a similar increase 
in creatinine, osmolar, and free water clearances 
during the first 12 hours in all groups, with a 
subsequent fall in levels in all groups 12 and 36 
hours after CPB (Table IV). Fractional sodium and 
potassium excretions also increased after the oper- 
ation in all groups; however, no statistically signifi- 
cant differences were found among the groups at 
any time. 
Graft patency assessment. A total of 183 vein 
grafts and 170 arterial grafts were performed in 120 
patients. The distribution of vein grafts (p = 0.22) 
and arterial grafts (p = 0.17) did not differ signifi- 
cantly among the groups. Also, no significant differ- 
ences in patency rates of vein grafts and arterial 
grafts were detected among the three groups either 
on a per-graft basis or on a per-patient basis (Table 
V). 
Clinical outcomes. No significant allergic reac- 
tion to aprotinin was observed in 110 patients who 
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Fig. 1. The antithrombin III (ATIII) and the fibrinogen 
levels were significantly (/9 < 0.05) decreased and the 
thrombin-antithrombin IlI complexes (T-AT III) signifi- 
cantly (p < 0.05) increased after CPB in all groups; 
however, no significant differences in those parameters 
were found among the groups at any time point. Control, 
Control group; Minimal, minimal-dose group; Low, low- 
dose group; CPB, cardiopulmonary b pass; Pre CPB, 
before administration of heparin; Off CPB, 15 minutes 
after protamine administration; 12 hrs, 12 hours after 
cessation of CPB. 
received aprotinin. Three patients died, two in the 
control group and one in the low-dose group. One 
patient in the control group died of severe pulmo- 
nary dysfunction from an unknown cause after the 
operation. The other patient in the control group, 
who underwent CABG while in a state of cardio- 
Fig. 2. The plasminogen activator inhibitor-1 (PAI-1) 
and the c~2-plasmin i hibitor (Alpha 2-PI) levels were 
significantly greater in the minimal- and low-dose groups 
than in the control group after CPB. The D-dimer was 
significantly greater in the control group than in the 
low-dose group after CPB and 12 hours after CPB. 
Abbreviations as listed in Fig. 1. 
genic shock resulting from an acute myocardial 
infarction, died of multiple organ failure on postop- 
erative day 12. One patient in the low-dose group 
became profoundly hypotensive immediately after 
the administration of protamine and subsequently 
died of multiple organ failure on postoperative day 
19. Nine patients had a perioperative myocardial 
infarction (defined as the appearance of new Q 
waves with a concomitant rise in the MB fraction of 
creatine kinase)--five patients in the control group, 
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Table IV. Preoperative and postoperative r nal functions 
Control Minimal dose Low dose 
(n= 57) (n = 55) (n = 55) p Value 
Creatinine clearance (ml/min) 
Preop. 60.7 ± 3.0 51.9 ± 3.5 60.6 ± 4.4 0.16 
0-12 hours 107.5 _+ 11.1" 108.6 +_ 10.0" 84.1 _+ 8.9* 0.19 
12-36 hours 75.3 _+ 3.9 87.5 _+ 7.4 83.9 _+ 10.3 0.46 
Osmolar clearance (ml/min) 
Preop. 1.38 _+ 0.07 1.39 _+ 0.14 1.31 _+ 0.10 0.84 
0-12 hours 4.22 ± 0.22* 4.68 _+ 0.27* 4.09 _+ 0.18" 0.18 
12-36 hours 2.12 ± 0.10 2.27 ± 0.13 1.92 + 0.09 0.10 
Free water clearance (ml/min) 
Preop. -0.52 _+ 0.07 -0.47 _+ 0.11 -0.33 ± 0.11 0.35 
0-12 -1.46 + 0.12" -1.45 _+ 0.17" -1.01 _+ 0.19" 0.11 
12-36 hours -0 .74 _+ 0.09 -0.71 ± 0.11 -0.71 _+ 0.08 0.96 
Fractional sodium excretion (%) 
Preop. 0.86 _+ 0.06 1.08 _+ 0.13 0.95 _+ 0.09 0.23 
0-12 hours 1.63 ± 0.22* 2.71 + 0.40* 2.52 _+ 0.45* 0.08 
12-36 hours 1.14 ± 0.12 1.37 _+ 0.33 1.20 ± 0.47 0.87 
Fractional potassium excretion (%) 
Preop. 9.i ± 0.05 10.5 ± 1.0 8.9 ± 0.6 0.24 
0-12 hours 26.7 _+ 1.3" 32.3 _+ 2.4* 31.5 _+ 2.6* 0.13 
12-36 hours 21.8 _+ 1.6" 20.0 ± 2.6* 25.3 ± 7.3* 0.68 
Thep values refer to the results of one-way analysis of variance. AbbreviatiOns as listed in Tables I and II. 
*p < 0.05 versus preoperative value. 
Table V. Patency of saphenous vein grafts and arterial grafts 
Control (n = 38) Minimal dose (n : 41) Low dose (n = 41) p Value 
Patency of saphenous vein grafts 
Patent grafts/total grafts 61/65 65/66 60/65 0.25 
(per-graft basis) (93.8%) (98.5%) (92.3%) 
No. of patients with all grafts patent 34/38 40/41 36/41 0.24 
(per-patient basis) (89.5%) (97.6%) (87.8%) 
Patency of arterial grafts 
Patent grafts/total grafts 50/50 62/64 55/56 0.46 
(per-graft basis) (100%) (96.9%) (98.2%) 
No. of patients with all grafts patent 38/38 39/41 40/41 0.39 
(per-patient basis) (100%) (95.1%) (97.6%) 
one in the minimal-dose group, and three in the 
low-dose group. Nine patients had low-output Syn- 
drome after the operation (defined as a requirement 
for inotropic medication or balloon pump support, 
or both, because of a cardiac index of less than 2.1 L 
• rain 1 • m 2 and a systolic blood pressure less than 
90 mm Hg, despite an adequate preload and correc- 
tion of any electrolyte disorders)--five patients in 
the control group, one in the minimal-dose group, 
and three in the low-dose group. No significant 
differences were apparent in these results among the 
groups. 
Discussion 
Many studies have examined the hemostatic effi- 
cacy of aprotinin and have demonstrated significant 
reductions in postoperative blood loss and transfu- 
sion requirements in patients undergoing cardiac 
operations. 1-1° The efficacy of aprotinin as a hemo- 
static agent is unquestionable, but concerns about 
the side effects of aprotinin have been raised. A 
higher prevalence of postoperative renal dysfunc- 
tion and early vein graft occlusion has been reported 
in patients receiving high-dose aprotinin. 9-11 In pre- 
vious reports, high-dose aprotinin has been shown to 
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cause a transient decrease in tubular sodium reab- 
sorption.19, 20 It has been suggested that these side 
effects of aprotinin may be dose dependent. 21 In 
recent studies comparing low-dose aprotinin with 
placebo, low-dose aprotinin has been shown to 
prevent enhanced fibrinolysis and reduce postoper- 
ative blood loss. % 8 Furthermore, low-dose aprotinin 
was reported to be as effective as high-dose aproti- 
nin in preserving lycoprotein Ib receptors and 
reducing blood loss. 5 It seems reasonable, therefore, 
that the dose might be minimized to reduce the 
prevalence of side effects and the costs. However, 
minimal-dose aprotinin with hemostatic efficacy 
comparable with that of high-dose aprotinin and 
without any side effects has not yet been recom- 
mended. 
Hemostatic efficacy. Covino and colleagues 22re- 
ported that low-dose aprotinin (1 X 10 6 KIU in the 
priming solution and 0.5 × 10 6 KIU/hr during the 
operation) was effective in reducing blood loss and 
transfusion requirements, but quarter-dose aproti- 
nin (0.5 x 10 6 KIU in the pump prime and 0.25 x 
l 0  6 K IU /hr  during the operation) was not. Van 
Oeveren and colleagues 5 reported that low-dose 
aprotinin (2 × 10 6 KIU aprotinin only in the pump 
prime) preserved glycoprotein Ib receptor and re- 
duced blood loss and transfusion requirements sim- 
ilarly to high-dose aprotinin (bolus infusion of 2 x 
10 6 KIU aprotinin during induction of anesthesia 
followed by a continuous infusion of 0.5 x 10 6 
KIU/hr and additional bolus of 2 X 10 6 KIU apro- 
tinin in the pump prime). They concluded that the 
protection of the platelet adhesive capacity through 
the platelet glycoprotein Ib receptor was obtained 
when aprotinin was present in sufficient amounts 
(2 x 10 6 KIU in the pump prime) at the first pass of 
blood through a circuit containing a membrane 
oxygenator. In the present study, the minimal-dose 
aprotinin regimen reduced the postoperative blood 
loss and transfusion requirements similarly to the 
low-dose regimen. Therefore, the dose of 1 × 10 6 
KIU added only in the pump prime may be the 
acceptable minimum dose for the reduction of post- 
operative blood loss, whereas the dose of 0.5 x 10 6 
KIU may be insufficient to be effective. 
In previous reports, high-dose aprotinin has been 
shown to inhibit enhanced fibrinolytic activity during 
CPB and reduce postoperative blood loss. 3' 19 Re- 
cently, low-dose aprotinin was also reported to have 
an inhibitory effect on enhanced fibrinolytic activity 
by increasing o~2-antiplasmin a d by decreasing fi- 
brin(ogen) degradation products. 7' s In the present 
study, we also found that low-dose aprotinin in- 
creased a2-plasmin i hibitor, plasminogen activator 
inhibitor-l, and decreased D-dimer levels during 
CPB compared with levels found in the control 
group. Although minimal-dose aprotinin did not 
decrease D-dimer levels after CPB as the low-dose 
aprotinin did, it significantly increased the levels of 
the az-plasmin inhibitor and the plasminogen acti- 
vator inhibitor-1 compared with those of the control 
group. These results suggest that minimal-dose 
aprotinin also has an inhibitory effect on enhanced 
fibrinolytic activity after CPB, which is sufficient for 
the preservation of hemostatic efficacy. Our study 
also demonstrated that the marked reduction of 
antithrombin III and fibrinogen and the increase of 
the thrombin-antithrombin III complexes after CPB 
in both aprotinin groups were comparable with 
those in the control group. The results were similar 
to previous reports that describe the hemostatic 
mechanism of aprotinin. 3'7, s The similar changes 
between the control group and the aprotinin groups 
in regard to those clotting parameters suggest few 
additional inhibitory effects on the activation of the 
clotting system by the doses used in this study. 
However, aprotinin has been reported to prolong 
the activated clotting time synergetically through the 
intrinsic lotting pathway by inhibiting kallikrein in a 
dose-related manner. 6' 23 Therefore high-dose apro- 
tinin may have an inhibitory effect on the activation 
of the intrinsic lotting system, whereas lower doses 
may not. Thus there is a risk of underheparinization 
if the activated clotting time is used as a monitor of 
adequacy of heparinization when aprotinin is 
present. As suggested in a previous study, 24 the 
activated clotting time of greater than 400 seconds 
used in this study may have been inadequate in 
patients receiving aprotinin. 
Renal function. Blauhut and colleagues 19 re- 
ported the increase of fractional sodium excretion 
during late intraoperative and early postoperative 
stages, which might reflect incipient renal tubular 
failure. However, they also found that renal function 
was unremarkab!e 24hours after the operation. In 
the present study, fractional sodium excretion was 
slightly (p = 0.08) greater in aprotinin-treated pa- 
tients during the first 12 hours after CPB. The result, 
as other investigators suggested, 19'20 might reflect a 
transient reduction of sodium reabsorption caused 
by renal tubular insufficiency. However, fractional 
sodium excretions in all groups became virtually 
identical (p = 0.87) by 36 hours after CPB. Further- 
more, creatinine, osmolar, and free water clearances 
2 6 8 Hayashida et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
August 1997 
were above normal during the early postoperative 
period in all groups, and no significant differences 
were detected among the groups. The results sug- 
gested that aprotinin use was not associated with a 
significant increase in the prevalence of renal dys- 
function. Sundt and colleagues 1°reported that apro- 
tinin was associated with an increased risk of renal 
dysfunction in patients undergoing procedures on 
the thoracic or thoracoabdominal aorta in which 
hypothermic circulatory arrest was used. Other in- 
vestigators suggested that adverse ffects on renal 
function could be temperature dependent. 21 Be- 
cause the systemic temperature in our patients was 
not cooled below 30°C (mean systemic tempera- 
ture, 33 ° +_ 1 ° C), the effect of aprotinin use on renal 
function was not investigated under hypothermic 
conditions. Therefore further investigations regard- 
ing the effect of aprotinin on renal function should 
be performed in patients undergoing hypothermic 
CPB and in patients with preexisting renal impair- 
ment, 
Graft pateney. Cosgrove and colleagues 9 have 
shown a trend toward an increased incidence of 
myocardial infarction in aprotinin-treated patients. 
Postmortem findings in their study demonstrated 
acute vein occlusions and widespread thrombosis n 
the kidney, native coronary ~@sels, and cerebral 
vessels in isolated patients, The early formation of 
thrombi on pulmonary artery catheters in patients 
receiving high-dose aprotinin has also been re- 
portedy'26 Because of these reports, concerns of 
early vein graft occlusion in patients undergoing 
CABG have been raised. ,~! In contrast, several in- 
vestigators have demonstrated that aprotinin did not 
influence arly vein graft patency. 27-29 A multicenter 
study also has demonstrated that aprotinin was not 
associated with an increased risk of myocardial 
infarction in patients undergoing repeated CABG, 3° 
Using coronary arteriography in 120 patients, we 
also demonstrated that neither minimal-dose nor 
low-dose aprotinin contributed to the early vein 
graft occlusion and the prevalence of perioperative 
myocardial infarction. The results of our study and 
previous tudies 27-3° suggest hat aprotinin has no 
adverse ffect on early vein graft patency. However, 
inasmuch as 47 of 167 patients (28%) were excluded 
from the postoperative angiographic study, patient 
selection might have been biased. Moreover, be- 
cause the number of patients involved in the study 
was relatively small to detect a difference in low- 
incidence vents such as graft occlusion or renal 
dysfunction, the potential for a type II statistical 
error exists. Therefore further investigations involv- 
ing more patients are required to assert he conclu- 
sions regarding the incidence of complications in
association with aprotinin. 
So that the adverse side effects of systemic apro- 
tinin can be avoided, effects of topical application of 
low-dose aprotinin into the pericardial cavity have 
been investigated. 31-33 The technique has been re- 
ported to reduce postoperative blood loss and trans- 
fusion requirements without significant side ef- 
fects. 31-33 The technique therefore may provide a 
potential to amplify the hemostatic efficacy and 
consequently minimize the systemic use of the reg- 
imen. However, because the mechanism of topical 
aprotinin action is still unclear, further investiga- 
tions are required for its routine use. 
In summary, neither minimal-dose nor low-dose 
aprotinin was associated with a significant increase 
in the prevalence ofrenal dysfunction and early vein 
graft occlusion. Inhibition of fibrinolysis and signif- 
icant reductions of blood loss and transfusion re- 
quirements were demonstrated in patients receiving 
minimal-dose aprotinin, as well as in patients receiv- 
ing low-dose aprotinin. The results suggested that 
the dose of 1 × 10 6 KIU added to the pump prime 
was acceptably effective in reducing blood loss for 
primary CABG without significant side effects. Min- 
imal-dose aprotinin may provide the optimal risk/ 
benefit balance. 
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